Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection

Blood

Volumn 119, Issue 18, 2012, Pages 4192-4204

  Elahi, Shokrollah ^a   Niki, Toshiro ^b,c   Hirashima, Mitsuomi ^b,c   Horton, Helen ^a,d  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b KAGAWA UNIVERSITY   (Japan)

^c Research Center   (Japan)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; ECALECTIN; GLYCOPROTEIN; PROTEIN TIM 3; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION CONTROL; INFECTION SENSITIVITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; TANDEM REPEAT; TH1 CELL; VIRUS REPLICATION;

EID: 84860773241     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-389585     Document Type: Article

References (52)

1. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: The way forward. Science. 2008;321(5888):530-532.
2. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010; 464(7286):217-223.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-2220.
4. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86(3):367-377. (Pubitemid 26272077)
5. Chen H, Li C, Huang J, et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective up-regulation of p21. J Clin Invest. 2011;121(4): 1549-1560.
6. Matsumoto R, Matsumoto H, Seki M, et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem. 1998;273(27): 16976-16984. (Pubitemid 28311730)
7. Elahi S, Dinges WL, Lejarcegui N, et al. Protective HIV-specific CD8(+) T cells evade T(reg) cell suppression. Nat Med. 2011;17(8):989-995.
8. Hirashima M. Galectin, especially galectin- 9/ecalectin. Nihon Rinsho. 2005;63(suppl 8):133-136.
9. Irie A, Yamauchi A, Kontani K, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res. 2005;11(8):2962-2968. (Pubitemid 40525199)
10. Jayaraman P, Sada-Ovalle I, Beladi S, et al. Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med. 2010;207(11):2343-2354.
11. Kashio Y, Nakamura K, Abedin MJ, et al. Galectin-9 induces apoptosis through the calcium-calpaincaspase- 1 pathway. J Immunol. 2003;170(7):3631-3636. (Pubitemid 36359232)
12. Kobayashi T, Kuroda J, Ashihara E, et al. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia. 2010; 24(4):843-850.
13. Nagahara K, Arikawa T, Oomizu S, et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin- 9-Tim-3 interactions. J Immunol. 2008; 181(11):7660-7669.
14. Chen X, Song CH, Liu ZQ, et al. Intestinal epithelial cells express galectin-9 in patients with food allergy that plays a critical role in sustaining allergic status in mouse intestine. Allergy. 2011;66(8): 1038-1046.
15. Hirashima M. Ecalectin/galectin-9, a novel eosinophil chemoattractant: Its function and production. Int Arch Allergy Immunol. 2000;122(suppl 1):6-9. (Pubitemid 30326326)
16. Imaizumi T, Yoshida H, Nishi N, et al. Doublestranded RNA induces galectin-9 in vascular endothelial cells: Involvement of TLR3, PI3K, and IRF3 pathway. Glycobiology. 2007;17(7):12C- 15C. (Pubitemid 47050657)
17. Ishikawa A, Imaizumi T, Yoshida H, et al. Doublestranded RNA enhances the expression of galectin- 9 in vascular endothelial cells. Immunol Cell Biol. 2004;82(4):410-414. (Pubitemid 39141764)
18. Mengshol JA, Golden-Mason L, Arikawa T, et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One. 2010;5(3):e9504.
19. Wiersma VR, de Bruyn M, Helfrich W, Bremer E. Therapeutic potential of Galectin-9 in human disease [published online ahead of print, July 26, 2011]. Med Res Rev. doi:10.1002/med.20249.
20. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245- 1252. (Pubitemid 43045636)
21. Bi S, Hong PW, Lee B, Baum LG. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci U S A. 2011;108(26):10650-10655.
22. Koguchi K, Anderson DE, Yang L, O'Connor KC, Kuchroo VK, Hafler DA. Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med. 2006;203(6):1413-1418. (Pubitemid 43877603)
23. Golden-Mason L, Palmer BE, Kassam N, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol. 2009;83(18):9122-9130.
24. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008; 205(12):2763-2779.
25. Li XC, Turka LA. An update on regulatory T cells in transplant tolerance and rejection. Nat Rev Nephrol. 2010;6(10):577-583.
26. Sehrawat S, Reddy PB, Rajasagi N, Suryawanshi A, Hirashima M, Rouse BT. Galectin- 9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathog. 2010;6(5):e1000882.
27. Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology. 2011;21(10):1258-1265.
28. Nishi N, Itoh A, Fujiyama A, et al. Development of highly stable galectins: Truncation of the linker peptide confers protease-resistance on tandemrepeat type galectins. FEBS Lett. 2005;579(10): 2058-2064. (Pubitemid 40469670)
29. Sacha JB, Watkins DI. Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies. Nat Protoc. 2010;5(2): 239-246.
30. Chagan-Yasutan H, Saitoh H, Ashino Y, et al. Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy. Tohoku J Exp Med. 2009;218(4):285-292.
31. Sattentau QJ, Clapham PR, Weiss RA, et al. The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule. AIDS. 1988;2(2):101-105.
32. Bleul CC,Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A. 1997; 94(5):1925-1930. (Pubitemid 27113938)
33. Wang J, Harada A, Matsushita S, et al. IL-4 and a glucocorticoid up-regulate CXCR4 expression on human CD4+ T lymphocytes and enhance HIV-1 replication. J Leukoc Biol. 1998;64(5):642-649. (Pubitemid 28511985)
34. Cicala C, Martinelli E, McNally JP, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A. 2009;106(49):20877-20882.
35. De Calisto J, Villablanca EJ, Wang S, Bono MR, Rosemblatt M, Mora JR. T-cell homing to the gut mucosa: General concepts and methodological considerations. Methods Mol Biol. 2012;757:411-434.
36. Seki M, Oomizu S, Sakata KM, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127(1):78-88.
37. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817-825. (Pubitemid 23346378)
38. Zhang Y, Ma CJ, Wang JM, et al. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes. J Leukoc Biol. 2012; 91(2):189-196.
39. Markovic I, Stantchev TS, Fields KH, et al. Thiol/ disulfide exchange is a prerequisite for CXCR4- tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood. 2004;103(5):1586-1594. (Pubitemid 38268946)
40. Papandreou MJ, Barbouche R, Guieu R, et al. Mapping of domains on HIV envelope protein mediating association with calnexin and protein-disulfide isomerase. J Biol Chem. 2010;285(18): 13788-13796.
41. Mandel R, Ryser HJ, Ghani F, Wu M, Peak D. Inhibition of a reductive function of the plasma membrane by bacitracin and antibodies against protein disulfide-isomerase. Proc Natl Acad Sci U S A. 1993;90(9):4112-4116. (Pubitemid 23134176)
42. Pelletier I, Hashidate T, Urashima T, et al. Specific recognition of Leishmania major poly-beta-galactosyl epitopes by galectin-9: Possible implication of galectin-9 in interaction between L. major and host cells. J Biol Chem. 2003;278(25):22223-22230. (Pubitemid 36830268)
43. Liu FT, Rabinovich GA. Galectins: Regulators of acute and chronic inflammation. Ann N Y Acad Sci. 2010;1183:158-182.
44. NobumotoA, Nagahara K, Oomizu S, et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology. 2008;18(9):735-744.
45. DeKruyff RH, Bu X, Ballesteros A, et al. T cell/ transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol. 2010;184(4):1918-1930.
46. Bergamaschi A, David A, Le Rouzic E, Nisole S, Barre-Sinoussi F, Pancino G. The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages. J Virol. 2009; 83(23):12253-12265.
47. Wang D, de la Fuente C, Deng L, et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol. 2001;75(16):7266-7279. (Pubitemid 32737985)
48. Zhang J, Scadden DT, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest. 2007 117(2): 473-481 (Pubitemid 46203976)
49. Bieniasz PD. An intrinsic host defense against HIV-1 integration? J Clin Invest. 2007;117(2):302-304. (Pubitemid 46203956)
50. Chabot S, Kashio Y, Seki M, et al. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology. 2002;12(2):111-118. (Pubitemid 34428934)
51. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med. 2000;343(14):1020-1034.
52. Wagner N, Lohler J, Kunkel EJ, et al. Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature. 1996;382(6589):366- 370. (Pubitemid 26260466)